Home > List All Publishers > Austin Research Group

Austin Research Group

Austin Research Analytics Group (ARAG) is a privately-held firm that provides clinically-focused competitive intelligence research and analytic services to biotechnology and pharmaceutical companies. Founded in 2000, all of ARAG's research and analysis is conducted by a full-time staff of analysts and consultants with more than 30 years of collective industry experience in functions including, Clinical Development, Market Research & Forecasting, Product Management, and Business Development

List of reports from Austin Research Group

Alzheimer's Disease Clinical Trial Monitoring Brief 10/1/2007 \| published by: Austin Research Group ... on the profiled-disease; typically includes top-line information on: Epidemiology Patient Segmentation Clinical endpoints The Trial TRAX brief also contains analysis of the clinical landscape with assessments including: % utilization of key clinical endpoints Number of ... \| more... Search inside this report	$700.00
Rheumatoid Arthritis Clinical Trial Monitoring Brief 8/1/2007 \| published by: Austin Research Group ... the profiled-disease; typically includes top-line information on: Epidemiology Patient Segmentation Clinical endpoints The Trial TRAX brief also contains analysis of the clinical landscape with assessments including: % utilization of key clinical endpoints Number of ongoing ... \| more... Search inside this report	$600.00
Therapeutic Area Clinical Intelligence: Type-2 Diabetes Pipeline 6/1/2008 \| published by: Austin Research Group ... million by 2030. Thiazolidediones (PPAR gamma agonists), such as Actos and Avandia, are currently the market leading therapeutic agents used to treat patients with type-2 diabetes, with 2007 worldwide sales of $3.5 billion and $1.7 ... \| more... Search inside this report	$4,500.00
Therapeutic Clinical Intelligence - Psoriasis 7/1/2007 \| published by: Austin Research Group ... dominate the moderate-to-severe psoriasis therapeutic market. However, companies are aggressively developing both novel and second-generation compounds that have the potential to challenge the competitive position of these market leaders in the future. Potential threats on ... \| more... Search inside this report	$900.00
Therapeutic Clinical Intelligence - Rheumatoid Arthritis 1/1/2009 \| published by: Austin Research Group ... changes over the past 5-10 years with the introduction of biologic, Disease Modifying Antirheumatic Drugs (DMARDs)—specifically, the Tumor Necrosis Factor-alpha (TNF-á) class of protein therapeutics. Products such as Enbrel (etanercept), Remicade (infliximab), and Humira (adalimumab) ... \| more... Search inside this report	$2,300.00
Therapeutic Clinical Intelligence-Inflammatory Bowel Disease 3/8/2007 \| published by: Austin Research Group ... Humira, Tysabri,Cimzia. Humira (adalimumab) was approved in January 2007 for CD and will compete with Remicade based upon relative efficacy & convenience (Pen Injector); while despite the fact that Tysabri¡¦s (natalizumab/VLA-4) safety will dampen initial ... \| more... Search inside this report	$3,100.00
Therapeutic Clinical Intelligence-Multiple Sclerosis 4/9/2007 \| published by: Austin Research Group ... Sclerosis (MS) from a clinical perspective. This methodological approach is intended to provide insight into the strategic opportunities and challenges, as well as the clinical hurdles facing MS drug developers. Specifically, the focus of our ... \| more... Search inside this report	$4,100.00
Trial TRAX Multiple Sclerosis Clinical Trial Monitoring Brief 10/1/2007 \| published by: Austin Research Group ... treatments that offer superior convenience, efficacy, and quality of life for MS patients. The strong trend in the increased competitiveness of the oral class is also validated by the R&D efforts of the MS market ... \| more... Search inside this report	$1,000.00